Citations

Clear

4207 citation(s) found for "Yu, Chen".

Type II mast cells in mast cell leukemia: Uncommon yet clinically significant
Chen, Constance P. , Chen, Dong , Chen, Dong

Mayo Clinic

eJHaem | April 8, 2024 | Volume: 5 | Issue: 2 | Pages: 412-413

10.1002/jha2.893 | PMID 38633112 Get It

Gammopathic dermopathy: characterization of cutaneous MGUS
Gordon, Emily R. , Chen, Caroline, Trager, Megan H. , Adeuyan, Oluwaseyi , Fahmy, Lauren M. , Schreidah, Celine M. , Wetter, David A. , Lapolla, Brigit A. , Geskin, Larisa J.

Mayo Clinic

Leukemia & Lymphoma | April 6, 2024 | Volume: 65 | Issue: 7 | Pages: 989-996

10.1080/10428194.2024.2336046 | PMID 38581379 Get It

5-Year Follow-Up of a Physician Performance Feedback Report Intervention to Reduce Overuse and Excess Cost: A National Cohort Study
Walsh, Christi, Stasko, Thomas, Vidimos, Allison T. , Leshin, Barry, Billingsley, Elizabeth M. , Coldiron, Brett M., Bennett, Richard G. , Marks, Victor J., Otley, Clark C. , Rogers, Howard W., Goldman, Glenn D., Albertini, John G., Makary, Martin A. , Dun, Chen , Hicks, Caitlin W.

Mayo Clinic

Dermatologic Surgery | April 5, 2024 | Volume: 50 | Issue: 6 | Pages: 558-564

10.1097/dss.0000000000004165 | PMID 38578837 Get It

BACKGROUND Mohs micrographic surgery efficiently treats skin cancer through staged resection, but surgeons' varying resection rates may lead to higher medical costs. OBJECTIVE To evaluate the cost savings associated with a quality improvement. MATERIALS AND METHODS The authors conducted a retrospective cohort study using 100% Medicare fee-for-service claims data to identify the change of mean stages per case for head/neck (HN) and trunk/extremity (TE) lesions before and after the quality improvement intervention from 2016 to 2021. They evaluated surgeon-level change in mean stages per case between the intervention and control groups, as well as the cost savings to Medicare over the same time period. RESULTS A total of 2,014 surgeons performed Mohs procedures on HN lesions. Among outlier surgeons who were notified, 31 surgeons (94%) for HN and 24 surgeons (89%) for TE reduced their mean stages per case with a median reduction of 0.16 and 0.21 stages, respectively. Reductions were also observed among outlier surgeons who were not notified, reducing their mean stages per case by 0.1 and 0.15 stages, respectively. The associated total 5-year savings after the intervention was 92 million USD. CONCLUSION The implementation of this physician-led benchmarking model was associated with broad reductions of physician utilization and significant cost savings.
CLO24-088: Efficacy of Fruquintinib in Less Heavily Pretreated Patients (Pts) With Metastatic Colorectal Cancer (mCRC): Profile-Matched Data From FRESCO and FRESCO-2
Jones, Jeremy , Shen, Lin , Bai, Yuxian , Deng, Yanhong , Yang, Zhao, Schelman, William R., Qin, Shukui , Jones, Jeremy C , Dasari, Arvind , Eng, Cathy , Lonardi, Sara , García‐Carbonero, Rocio , Masuishi, Toshiki , Cremolini, Chiara , Ghiringhelli, François , Hubbard, Joleen M. , Bekaii‐Saab, Tanios , Xu, Rui‐Hua , Xu, Jianming , Yuan, Ying , Wei, Wei , Lin, Jianchang , Chen, Lucy L , Li, Jin

Mayo Clinic

Journal of the National Comprehensive Cancer Network | April 5, 2024 | Volume: 22 | Issue: 2.5 | Pages: No page available

10.6004/jnccn.2023.7171 Get It

Antibody-mediated targeting of human microglial leukocyte Ig-like receptor B4 attenuates amyloid pathology in a mouse model
Hou, Jinchao , Chen, Yun , Cai, Zhangying , Heo, Gyu Seong , Yuede, Carla M. , Wang, Z , Lin, Kent , Saadi, Fareeha , Tršan, Tihana , Nguyen, Aivi T. , Constantopoulos, Eleni , Larsen, Rachel A. , Zhu, Yiyang , Wagner, Nicole D. , McLaughlin, Nolan, Kuang, Xinyi Cynthia, Barrow, Alexander D. , Zhou, Yingyue , Gilfillan, Susan , Gross, Michael L. , Brioschi, Simone , Liu, Yongjian , Wang, Zuoxu , Li, Dian , Zhou, Yingyue , Wang, Shoutang , Gilfillan, Susan , Gross, Michael L , Brioschi, Simone , Liu, Yongjian , Holtzman, David M , Colonna, Marco , Nguyen, Aivi T , Holtzman, David M. , Colonna, Marco

Mayo Clinic

Science Translational Medicine | April 3, 2024 | Volume: 16 | Issue: 741 | Pages: No page available

10.1126/scitranslmed.adj9052 | PMID 38569016 Get It

Microglia help limit the progression of Alzheimer’s disease (AD) by constraining amyloid-β (Aβ) pathology, effected through a balance of activating and inhibitory intracellular signals delivered by distinct cell surface receptors. Human leukocyte Ig-like receptor B4 (LILRB4) is an inhibitory receptor of the immunoglobulin (Ig) superfamily that is expressed on myeloid cells and recognizes apolipoprotein E (ApoE) among other ligands. Here, we find that LILRB4 is highly expressed in the microglia of patients with AD. Using mice that accumulate Aβ and carry a transgene encompassing a portion of the LILR region that includes LILRB4 , we corroborated abundant LILRB4 expression in microglia wrapping around Aβ plaques. Systemic treatment of these mice with an anti-human LILRB4 monoclonal antibody (mAb) reduced Aβ load, mitigated some Aβ-related behavioral abnormalities, enhanced microglia activity, and attenuated expression of interferon-induced genes. In vitro binding experiments established that human LILRB4 binds both human and mouse ApoE and that anti-human LILRB4 mAb blocks such interaction. In silico modeling, biochemical, and mutagenesis analyses identified a loop between the two extracellular Ig domains of LILRB4 required for interaction with mouse ApoE and further indicated that anti-LILRB4 mAb may block LILRB4-mApoE by directly binding this loop. Thus, targeting LILRB4 may be a potential therapeutic avenue for AD.
The impact of cytotoxic therapy on the risk of progression and death in clonal cytopenia(s) of undetermined significance
Li, Marissa , Baranwal, Anmol , Gurney, Mark E. , Shah, Syed Nasir Ali, Al‐Kali, Aref , Foran, James M. , Yi, Cecilia Arana , Ongie, Laura , Mangaonkar, Abhishek A. , Tefferi, Ayalew , Lasho, Terra, Finke, Christy M. , Patnaik, Mrinal M. , Gurney, Mark , Shah, Syed N, Arana Yi, Cecilia , McCullough, Kristen B , Patnaik, Mrinal , Shah, Mithun V , Baranwal, Anmol , Li, Marissa M , Alkhateeb, Hassan B. , Chen, Dong , McCullough, Kristen , Lasho, Terra, Shah, Meera

Mayo Clinic

Blood Advances | April 2, 2024 | Volume: 8 | Issue: 12 | Pages: 3130-3139

10.1182/bloodadvances.2023012357 | PMID 38564774 Get It

Abstract Clonal cytopenia of undetermined significance (CCUS) is defined by a myeloid driver mutation in the context of otherwise unexplained cytopenia. CCUS has an inherent risk of progressing to myeloid neoplasm. However, it is unknown how exposure to previous cytotoxic therapy may impact the risk of progression and survival. We stratified patients with CCUS by prior exposure to DNA-damaging therapy. Of 151 patients, 46 (30%) had received cytotoxic therapy and were classified as therapy-related CCUS (t-CCUS), whereas 105 (70%) had de novo CCUS. A lower proportion of t-CCUS had hypercellular marrows (17.8% vs 44.8%, P = .002) but had higher median bone marrow blast percentages. After a median follow-up of 2.2 years, t-CCUS had significantly shorter progression-free survival (PFS, 1.8 vs 6.3 years; hazard ratio [HR], 2.1; P = .007) and median overall survival (OS; 3.6 years vs not reached; HR, 2.3; P = .007) compared with CCUS. Univariable and multivariable time-to-event analyses showed that exposure to cytotoxic therapy independently accounted for inferior PFS and OS. Despite the similarities in clinical presentation between CCUS and t-CCUS, we show that exposure to prior cytotoxic therapies was an independent risk factor for inferior outcomes. This suggests that t-CCUS represents a unique clinical entity that needs more stringent monitoring or earlier intervention strategies.
Combining Blood-Based Biomarkers and Structural MRI Measurements to Distinguish Persons with and without Significant Amyloid Plaques
Chen, Yanxi , Initiative, for the Alzheimer’s Disease Neuroimaging, Wu, Jianfeng , Caselli, Richard J. , Reiman, Eric M. , Su, Yi, Su, Yi , Chen, Kewei, Atri, Alireza, Wang, Yalin, Initiative, the Alzheimer’s Disease Neuroimaging

Mayo Clinic

Journal of Alzheimer's Disease | April 2, 2024 | Volume: 98 | Issue: 4 | Pages: 1415-1426

10.3233/jad-231162 | PMID 38578889 Get It

Background: Amyloid-β (Aβ) plaques play a pivotal role in Alzheimer’s disease. The current positron emission tomography (PET) is expensive and limited in availability. In contrast, blood-based biomarkers (BBBMs) show potential for characterizing Aβ plaques more affordably. We have previously proposed an MRI-based hippocampal morphometry measure to be an indicator of Aβ plaques. Objective: To develop and validate an integrated model to predict brain amyloid PET positivity combining MRI feature and plasma Aβ42/40 ratio. Methods: We extracted hippocampal multivariate morphometry statistics from MR images and together with plasma Aβ42/40 trained a random forest classifier to perform a binary classification of participant brain amyloid PET positivity. We evaluated the model performance using two distinct cohorts, one from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) and the other from the Banner Alzheimer’s Institute (BAI), including prediction accuracy, precision, recall rate, F1 score, and AUC score. Results: Results from ADNI (mean age 72.6, Aβ+ rate 49.5%) and BAI (mean age 66.2, Aβ+ rate 36.9%) datasets revealed the integrated multimodal (IMM) model’s superior performance over unimodal models. The IMM model achieved prediction accuracies of 0.86 in ADNI and 0.92 in BAI, surpassing unimodal models based solely on structural MRI (0.81 and 0.87) or plasma Aβ42/40 (0.73 and 0.81) predictors. CONCLUSIONS: Our IMM model, combining MRI and BBBM data, offers a highly accurate approach to predict brain amyloid PET positivity. This innovative multiplex biomarker strategy presents an accessible and cost-effective avenue for advancing Alzheimer’s disease diagnostics, leveraging diverse pathologic features related to Aβ plaques and structural MRI.
Management of undifferentiated embryonal sarcoma of the liver: A Pediatric Surgical Oncology Research Collaborative study
Kastenberg, Zachary J. , Short, Scott S. , Riehle, Kimberly J. , Lautz, Timothy B. , Ott, Katherine C. , Murphy, Andrew J. , Mansfield, Sara A. , Hallis, Brian, Murphy, Joseph, Roach, Jonathan P. , Polites, Stephanie F. , Beckhorn, Catherine B , Fialkowski, Elizabeth , Seemann, Natashia M. , Bütter, Andreana , Rich, Barrie S. , Glick, Richard D. , Bondoc, Alex, Ofori-Atta, Blessing , Zamora, Abigail K., Vasudevan, Sanjeev A. , Rinehardt, Hannah , Lapidus‐Krol, Eveline , Meyers, Rebecka L. , Tiao, Greg , Dasgupta, Roshni , Baertschiger, Reto M. , Lautz, Timothy , Murphy, Andrew J , Beckhorn, Catherine , Tracy, Elisabeth T , Fialkowski, Elizabeth A , Seemann, Natashia M , Malek, Marcus M , Baertschiger, Reto , Kastenberg, Zachary J , Dasgupta, Roshni , Utria, Alan Fremder , Lal, Dave R. , Tracy, Elisabeth T. , Bondoc, Alexander , Presson, Angela P. , Chen, Stephanie , Kim, Eugene S. , Malek, Marcus M. , Putra, Juan , Superina, Riccardo Antonio , Langham, Max Raymond

Mayo Clinic

Pediatric Blood & Cancer | April 1, 2024 | Volume: 71 | Issue: 6 | Pages: No page available

10.1002/pbc.30975 | PMID 38556718 Get It

AbstractBackgroundUndifferentiated embryonal sarcoma of the liver (UESL) is a rare tumor for which there are few evidence‐based guidelines. The aim of this study was to define current management strategies and outcomes for these patients using a multi‐institutional dataset curated by the Pediatric Surgical Oncology Research Collaborative.MethodsData were collected retrospectively for patients with UESL treated across 17 children's hospitals in North America from 1989 to 2019. Factors analyzed included patient and tumor characteristics, PRETEXT group, operative details, and neoadjuvant/adjuvant regimens. Event‐free and overall survival (EFS, OS) were the primary and secondary outcomes, respectively.ResultsSeventy‐eight patients were identified with a median age of 9.9 years [interquartile range [IQR): 7–12]. Twenty‐seven patients underwent resection at diagnosis, and 47 patients underwent delayed resection, including eight liver transplants. Neoadjuvant chemotherapy led to a median change in maximum tumor diameter of 1.6 cm [IQR: 0.0–4.4] and greater than 90% tumor necrosis in 79% of the patients undergoing delayed resection. R0 resections were accomplished in 63 patients (81%). Univariate analysis found that metastatic disease impacted OS, and completeness of resection impacted both EFS and OS, while multivariate analysis revealed that R0 resection was associated with decreased expected hazards of experiencing an event [hazard ratio (HR): 0.14, 95% confidence interval (CI): 0.04–0.6]. At a median follow‐up of 4 years [IQR: 2–8], the EFS was 70.0% [95% CI: 60%–82%] and OS was 83% [95% CI: 75%–93%].ConclusionComplete resection is associated with improved survival for patients with UESL. Neoadjuvant chemotherapy causes minimal radiographic response, but significant tumor necrosis.
Monoclonal antibody therapies for aquaporin-4-immunoglobulin G-positive neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease
Juan, Hui Yu, Chen, John J. , Chen, John J , Tisavipat, Nanthaya

Mayo Clinic

Saudi Journal of Ophthalmology | March 29, 2024 | Volume: 38 | Issue: 1 | Pages: 2-12

10.4103/sjopt.sjopt_102_23 | PMID 38628414 Get It

Abstract: Monoclonal antibody therapies mark the new era of targeted treatment for relapse prevention in aquaporin-4 (AQP4)-immunoglobulin G (IgG)-positive neuromyelitis optica spectrum disorder (AQP4-IgG+NMOSD). For over a decade, rituximab, an anti-CD20 B-cell-depleting agent, had been the most effectiveness treatment for AQP4-IgG+NMOSD. Tocilizumab, an anti-interleukin-6 receptor, was also observed to be effective. In 2019, several randomized, placebo-controlled trials were completed that demonstrated the remarkable efficacy of eculizumab (anti-C5 complement inhibitor), inebilizumab (anti-CD19 B-cell-depleting agent), and satralizumab (anti-interleukin-6 receptor), leading to the Food and Drug Administration (FDA) approval of specific treatments for AQP4-IgG+NMOSD for the first time. Most recently, ravulizumab (anti-C5 complement inhibitor) was also shown to be highly efficacious in an open-label, external-controlled trial. Although only some patients with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) warrant immunotherapy, there is currently no FDA-approved treatment for relapse prevention in MOGAD. Observational studies showed that tocilizumab was associated with a decrease in relapses, whereas rituximab seemed to have less robust effectiveness in MOGAD compared to AQP4-IgG+NMOSD. Herein, we review the evidence on the efficacy and safety of each monoclonal antibody therapy used in AQP4-IgG+NMOSD and MOGAD, including special considerations in children and women of childbearing potential.
Optimal Implant Sizing Using Machine Learning Is Associated With Increased Range of Motion After Cervical Disk Arthroplasty
Lakomkin, Nikita , Pennington, Zach , Bhandarkar, Archis R. , Mikula, Anthony L. , Chen, Selby , McClendon, Jamal, Freedman, Brett A. , Bydon, Mohamad , Bhandarkar, Archis, Katsos, Konstantinos, Pennington, Zach , Michalopoulos, Giorgos D. , Katsos, Konstantinos

Mayo Clinic

Neurosurgery | March 29, 2024 | Volume: 95 | Issue: 3 | Pages: 627-633

10.1227/neu.0000000000002924 | PMID 38551347 Get It

BACKGROUND AND OBJECTIVES: Cervical disk arthroplasty (CDA) offers the advantage of motion preservation in the treatment of focal cervical pathology. At present, implant sizing is performed using subjective tactile feedback and imaging of trial cages. This study aims to construct interpretable machine learning (IML) models to accurately predict postoperative range of motion (ROM) and identify the optimal implant sizes that maximize ROM in patients undergoing CDA. METHODS: Adult patients who underwent CDA for single-level disease from 2012 to 2020 were identified. Patient demographics, comorbidities, and outcomes were collected, including symptoms, examination findings, subsidence, and reoperation. Affected disk height, healthy rostral disk height, and implant height were collected at sequential time points. Linear regression and IML models, including bagged regression tree, bagged multivariate adaptive regression spline, and k-nearest neighbors, were used to predict ROM change. Model performance was assessed by calculating the root mean square error (RMSE) between predicted and actual changes in ROM in the validation cohort. Variable importance was assessed using RMSE loss. Area under the curve analyses were performed to identify the ideal implant size cutoffs in predicting improved ROM. RESULTS: Forty-seven patients were included. The average RMSE between predicted and actual ROM was 7.6° (range: 5.8-10.1) in the k-nearest neighbors model, 7.8° (range: 6.5-10.0) in the bagged regression tree model, 7.8° (range: 6.2-10.0) in the bagged multivariate adaptive regression spline model, and 15.8° (range: 14.3-17.5°) in a linear regression model. In the highest-performing IML model, graft size was the most important predictor with RMSE loss of 6.2, followed by age (RMSE loss = 5.9) and preoperative caudal disk height (RMSE loss = 5.8). Implant size at 110% of the normal adjacent disk height was the optimal cutoff associated with improved ROM. CONCLUSION: IML models can reliably predict change in ROM after CDA within an average of 7.6 degrees of error. Implants sized comparably with the healthy adjacent disk may maximize ROM.